• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SWI/SNF复合体核心亚基的蛋白质丢失对肝内和肝外胆管癌组织学亚型的预后有影响。

Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma.

作者信息

Wagner Britta Janina, Plum Patrick Sven, Apel Katharina, Scherer Marie, Buchner Denise, Brinkmann Sebastian, Buettner Reinhard, Stippel Dirk, Quaas Alexander, Drebber Uta

机构信息

Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.

Department of General, Visceral, Cancer and Transplant Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, D-50937 Cologne, Germany.

出版信息

Oncol Lett. 2021 May;21(5):349. doi: 10.3892/ol.2021.12610. Epub 2021 Mar 3.

DOI:10.3892/ol.2021.12610
PMID:33747206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7968003/
Abstract

Cholangiocarcinoma (CCA) is an aggressive malignancy with a 5-year-survival rate of <10%, mainly due to diagnosis in advanced stages and limited therapeutic options in case of progressive disease. Recently, evidence has indicated that alterations in the SWI/SNF-complex (SWI/SNF) may have an important role in the tumorigenesis of CCA. SWI/SNF-related chromatin remodeling has been reported to be crucial for differentiation and tumor suppression, and loss-of-function mutations of SWI/SNF are present in 20% of human malignancies; however, at present, little is known about its relevance in CCA. In the present study, a cohort of 52 patients with the diagnosis of primary CCA was retrospectively collected. All patients underwent surgery with curative intent. Tissue microarray analysis was performed on each tumor for immunohistochemical loss-of-protein analysis of the SWI/SNF core subunits ARID1A, INI-1, BRG1, PBRM-1 and BRM, corresponding to the following CCA subtypes: Extrahepatic CCA (ECCA), small duct or large duct intrahepatic CCA (ICCA). Kaplan-Meier analysis was used to determine survival distribution and survival differences were evaluated by log-rank test. In total, 14 of 52 patients (~35%) exhibited protein-loss of any tested SWI/SNF core subunit. Notably, 17% of patients exhibited a loss of ARID1a; this was the protein loss with the highest frequency. Patients with small and large duct ICCA with protein-loss of any tested SWI/SNF subunit exhibited significantly worse survival compared with the wild-type cohort with proficient protein expression (P=0.013 and P=0.002), whereas no significant survival difference was detected for patients with ECCA. SWI/SNF and its core subunits may be considered promising predictive and therapeutic targets, and require further investigation in patients with CCA.

摘要

胆管癌(CCA)是一种侵袭性恶性肿瘤,5年生存率<10%,主要原因是其常在晚期才被诊断出来,且疾病进展时治疗选择有限。最近,有证据表明,SWI/SNF复合物(SWI/SNF)的改变可能在CCA的肿瘤发生中起重要作用。据报道,SWI/SNF相关的染色质重塑对于细胞分化和肿瘤抑制至关重要,并且SWI/SNF的功能丧失突变存在于20%的人类恶性肿瘤中;然而,目前对其在CCA中的相关性知之甚少。在本研究中,回顾性收集了52例诊断为原发性CCA的患者队列。所有患者均接受了根治性手术。对每个肿瘤进行组织微阵列分析,以对SWI/SNF核心亚基ARID1A、INI-1、BRG1、PBRM-1和BRM进行免疫组化蛋白缺失分析,这些亚基对应于以下CCA亚型:肝外CCA(ECCA)、小胆管或大胆管肝内CCA(ICCA)。采用Kaplan-Meier分析确定生存分布,并通过对数秩检验评估生存差异。总共52例患者中有14例(约35%)表现出任何测试的SWI/SNF核心亚基的蛋白缺失。值得注意的是,17%的患者表现出ARID1a缺失;这是频率最高的蛋白缺失。任何测试的SWI/SNF亚基蛋白缺失的小胆管和大胆管ICCA患者与蛋白表达正常的野生型队列相比,生存率显著更差(P=0.013和P=0.002),而ECCA患者未检测到显著的生存差异。SWI/SNF及其核心亚基可能被认为是有前景的预测和治疗靶点,需要在CCA患者中进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/54a7cd608c40/ol-21-05-12610-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/2516b0d288d1/ol-21-05-12610-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/1ce43fb6780b/ol-21-05-12610-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/496f9df0d434/ol-21-05-12610-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/e07c6b055b6f/ol-21-05-12610-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/54a7cd608c40/ol-21-05-12610-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/2516b0d288d1/ol-21-05-12610-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/1ce43fb6780b/ol-21-05-12610-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/496f9df0d434/ol-21-05-12610-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/e07c6b055b6f/ol-21-05-12610-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5830/7968003/54a7cd608c40/ol-21-05-12610-g04.jpg

相似文献

1
Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma.SWI/SNF复合体核心亚基的蛋白质丢失对肝内和肝外胆管癌组织学亚型的预后有影响。
Oncol Lett. 2021 May;21(5):349. doi: 10.3892/ol.2021.12610. Epub 2021 Mar 3.
2
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.食管腺癌中 SWI/SNF-ATP 酶亚基成员 SMARCF1(ARID1A)、SMARCA2(BRM)、SMARCA4(BRG1)和 SMARCB1(INI1)的缺失。
BMC Cancer. 2020 Jan 6;20(1):12. doi: 10.1186/s12885-019-6425-3.
3
Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.BRG1 和 BRM 通过相互排斥的 SWI/SNF ATPase 亚基共同调节转录。
Epigenetics Chromatin. 2017 Dec 22;10(1):62. doi: 10.1186/s13072-017-0167-8.
4
SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study.SWI/SNF 染色质重塑复合物在胰腺导管腺癌中的表达:临床病理和免疫组织化学研究。
Hum Pathol. 2024 Feb;144:40-45. doi: 10.1016/j.humpath.2024.01.013. Epub 2024 Feb 1.
5
alterations and their clinical significance in cholangiocarcinoma.胆管癌的改变及其临床意义
PeerJ. 2020 Dec 3;8:e10464. doi: 10.7717/peerj.10464. eCollection 2020.
6
Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.对SWI/SNF复合物表达的综合评估确定了卵巢透明细胞癌的两种不同预后亚型。
Oncotarget. 2016 Aug 23;7(34):54758-54770. doi: 10.18632/oncotarget.10181.
7
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.SWI/SNF 复合物表达缺失的非小细胞肺癌与侵袭性临床病理特征、PD-L1 阳性状态和高肿瘤突变负担相关。
Lung Cancer. 2019 Dec;138:35-42. doi: 10.1016/j.lungcan.2019.10.009. Epub 2019 Oct 13.
8
BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?BRM:SWI/SNF 染色质重塑复合物的核心 ATP 酶亚基——抑癌因子还是促癌因子?
Epigenetics Chromatin. 2019 Nov 13;12(1):68. doi: 10.1186/s13072-019-0315-4.
9
Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.超越突变:SWI/SNF 复合物失活的其他机制和影响。
Front Oncol. 2015 Feb 27;4:372. doi: 10.3389/fonc.2014.00372. eCollection 2014.
10
BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions .BRG1和BRM缺失分别选择性地影响RB和P53:BRG1和BRM具有不同的功能。
Oncoscience. 2016 Dec 21;3(11-12):337-350. doi: 10.18632/oncoscience.333. eCollection 2016.

引用本文的文献

1
Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut-Liver Axis in Tumorigenesis and Therapy.肝癌中的基因组改变与微生物群串扰:肿瘤发生与治疗中的肠-肝轴
Genes (Basel). 2025 Jul 30;16(8):920. doi: 10.3390/genes16080920.
2
Therapy-relevant amplification in cholangiocarcinomas in Caucasian patients.高加索患者胆管癌中与治疗相关的扩增
Ther Adv Med Oncol. 2024 Nov 9;16:17588359241288123. doi: 10.1177/17588359241288123. eCollection 2024.
3
SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.

本文引用的文献

1
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.食管腺癌中 SWI/SNF-ATP 酶亚基成员 SMARCF1(ARID1A)、SMARCA2(BRM)、SMARCA4(BRG1)和 SMARCB1(INI1)的缺失。
BMC Cancer. 2020 Jan 6;20(1):12. doi: 10.1186/s12885-019-6425-3.
2
The 2019 WHO classification of tumours of the digestive system.2019年世界卫生组织消化系统肿瘤分类。
Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13.
3
Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
SWI/SNF 复合物缺陷型胰腺未分化癌:临床病理和基因组分析。
Mod Pathol. 2024 Nov;37(11):100585. doi: 10.1016/j.modpat.2024.100585. Epub 2024 Jul 31.
4
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.欧洲肝内胆管癌的综合基因组分析:新型 ROS1 融合基因和 PBX1 作为预后标志物。
Clin Transl Med. 2024 Jun;14(6):e1723. doi: 10.1002/ctm2.1723.
5
Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.世界卫生组织肝内胆管癌亚型分类的外科解读:一篇综述
Surg Today. 2025 Jan;55(1):1-9. doi: 10.1007/s00595-024-02825-x. Epub 2024 Apr 2.
6
Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.胆管癌的精准医学:过去、现在与未来
Life (Basel). 2022 Jun 2;12(6):829. doi: 10.3390/life12060829.
7
Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.胆管癌的变异:临床意义与分子机制
Front Oncol. 2021 Jun 25;11:693295. doi: 10.3389/fonc.2021.693295. eCollection 2021.
BAP-1 和 PBRM-1 表达在肝内胆管癌中的预后作用。
Virchows Arch. 2019 Jan;474(1):29-37. doi: 10.1007/s00428-018-2478-y. Epub 2018 Oct 30.
4
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.在预后分层组中进行的遗传改变分析表明,TP53 和 ARID1A 是肝内胆管癌临床不良表现的标志物。
Sci Rep. 2018 May 8;8(1):7119. doi: 10.1038/s41598-018-25669-1.
5
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.ARID1A 缺失可促进突变并增强免疫检查点阻断引发的抗肿瘤治疗性免疫。
Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7.
6
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.BGJ398 治疗 FGFR 改变的晚期胆管癌患者的 II 期研究。
J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
7
Cholangiocarcinoma - evolving concepts and therapeutic strategies.胆管癌——不断演变的概念与治疗策略
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10.
8
AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.AKT抑制是ARID1A缺陷型胃癌细胞中的一种有效治疗策略。
Onco Targets Ther. 2017 Aug 22;10:4153-4159. doi: 10.2147/OTT.S139664. eCollection 2017.
9
Epidemiology and risk factors: intrahepatic cholangiocarcinoma.流行病学与危险因素:肝内胆管癌
Hepatobiliary Surg Nutr. 2017 Apr;6(2):101-104. doi: 10.21037/hbsn.2017.01.02.
10
Composition and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Disease.哺乳动物SWI/SNF染色质重塑复合物在人类疾病中的组成与功能
Cold Spring Harb Symp Quant Biol. 2016;81:53-60. doi: 10.1101/sqb.2016.81.031021. Epub 2017 Apr 13.